Cyclacel to Present Preclinical Data on Lead Clinical-Stage Drug, Seliciclib, at American Association for Cancer Research Annual Meeting.SHORT HILLS, N.J. -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC CYCC Canadian Youth Climate Coalition ) announced today that scientists from the company will present results of two preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. supporting the synergistic activity of Cyclacel's lead anticancer drug anticancer drug see antineoplastic. anticancer drug Chemotherapeutic, see there , seliciclib, in combination with other molecularly targeted anticancer agents and in addition report findings on the mechanism of action of seliciclib. The results will be reported in two poster presentations during the upcoming Annual Meeting of the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational (AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved ) taking place in Washington, D.C. between April 1-5, 2006. Seliciclib is the most advanced orally-available cyclin cy·clin n. A class of proteins that fluctuate in concentration at specific points during the cell cycle and that regulate the cycle by binding to a kinase. dependent kinase (CDK Cdk cyclin-dependent protein kinase. ) inhibitor now in Phase II clinical trials in patients with non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. . Seliciclib is the lead drug candidate in Cyclacel's pipeline of small molecule cell cycle inhibitors. The first poster will report findings regarding the mechanism of action of seliciclib and related follow-on compounds in multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility cells, a hematologic malignancy hematologic malignancy Hematologic cancer Hematology Any CA of blood-forming tissues, BM, or lymph nodes–eg, leukemia and lymphoma . The second poster will report results of in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. drug combination studies evaluating on non-small cell lung cancer cells the effects of seliciclib administered in combination with other molecularly targeted anticancer agents. Details of the poster presentations and related bibliographical citations are as follows: Monday, April 3, 2006 -- Novel cyclin dependent kinase (CDK) inhibitors induce down regulation of Mcl-1 and apoptosis in multiple myeloma cells. Abstract Number: 2069. Citation: MacCallum, D.E. et al. Novel cyclin dependent kinase (CDK) inhibitors induce down regulation of Mcl-1 and apoptosis in multiple myeloma cells. Proc. Amer. Assoc. Cancer Res. 2006; 47: 2069. Tuesday, April 4, 2006 -- Combination analysis between seliciclib (CYC202; R-roscovitine) and other molecularly targeted anticancer agents in non-small cell lung cancer. Abstract number: 3838. Citation: Fleming, I.N., et al. Combination analysis between seliciclib (CYC202; R-roscovitine) and other molecularly targeted anticancer agents in non-small cell lung cancer. Proc. Amer. Assoc. Cancer Res. 2006; 47: 3838. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The company is currently evaluating seliciclib (CYC202), an orally-available cyclin dependent kinase inhibitor, in Phase II clinical trials for the treatment of lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . Sapacitabine (CYC682) is an orally-available, cell cycle modulating nucleoside analog in Phase I clinical trials for the treatment of cancer. CYC116 is an orally-available, Aurora kinase inhibitor in IND-directed preclinical development. Several additional programs are at an earlier stage. Note: The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc. Risk Factors This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Form S-4 (File No. 333-131225) filed with the SEC in connection with the transactions. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion